Abivax presents first-half 2023 financial results

PARIS, FRANCE / ACCESSWIRE / September 21, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory …